Fernando Maria De Benedictis
Research Subjects
Fernando Maria De Benedictis has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
David Selvaggio
Department of Pediatric Medicine, ‘Salesi’ Childrens’ Hospital, Ancona, Italy
2 shared publicationsP Osimani
Department of Pediatrics, Salesi Children’s Hospital, Ancona, Italy
2 shared publicationsS. Vaccher
2 shared publicationsA. Capristo
1 shared publicationAlessandro Tronci
1 shared publication- Ascanio Martino
Division of Pediatric Surgery, AziendaOspealiero-Universitaria "Ospedali Riuniti", Ancona, Italy
1 shared publication
Latest Publications
- Open Access
- 8 August 2025
- Published by BMJ in BMJ Case Reports
- Vol. 2009, 2008141
Necrotising fasciitis complicating varicella
- 8 August 2025
- Published by BMJ in BMJ Case Reports
- Vol. 2009, 2008141
Open AccessNecrotising fasciitis complicating varicella
- 6 May 2010
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 40 (6) , 951
Spirometry in children with allergic rhinitis
- 6 May 2010
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 40 (6) , 951
Spirometry in children with allergic rhinitis
- 14 April 2009
- Published by Springer Nature in Pediatric Cardiology
- Vol. 30 (6) , 837-839
Amino-Terminal Pro-B-Type Natriuretic Peptide in Refractory Kawasaki Disease
Serum concentrations of brain natriuretic peptide and its amino-terminal cleavage pro-fragment, NT-proBNP, have never been reported in refractory Kawasaki disease. Changes in NT-proBNP levels after infliximab treatment in an infant with severe cardiovascular complications are reported here. The regular evaluation of this cardiac biomarker after infliximab treatment may have clinical relevance in patients with refractory Kawasaki disease and severe heart involvement.
- 14 April 2009
- Published by Springer Nature in Pediatric Cardiology
- Vol. 30 (6) , 837-839
Amino-Terminal Pro-B-Type Natriuretic Peptide in Refractory Kawasaki Disease
Serum concentrations of brain natriuretic peptide and its amino-terminal cleavage pro-fragment, NT-proBNP, have never been reported in refractory Kawasaki disease. Changes in NT-proBNP levels after infliximab treatment in an infant with severe cardiovascular complications are reported here. The regular evaluation of this cardiac biomarker after infliximab treatment may have clinical relevance in patients with refractory Kawasaki disease and severe heart involvement.
- 1 February 2009
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 56 (1) , 173-190
Aspiration Lung Disease
- 1 February 2009
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 56 (1) , 173-190
Aspiration Lung Disease
- Open Access
- 1 January 2009
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 35 (1) , 21
Exhaled nitric oxide measurements in the first 2 years of life: methodological issues, clinical and epidemiological applications
Fractional exhaled nitric oxide (FeNO) is a useful tool to diagnose and monitor eosinophilic bronchial inflammation in asthmatic children and adults. In children younger than 2 years of age FeNO has been successfully measured both with the tidal breathing and with the single breath techniques. However, there are a number of methodological issues that need to be addressed in order to increase the reproducibility of the FeNO measurements within and between infants. Indeed, a standardized method to measure FeNO in the first 2 years of life would be extremely useful in order to meaningfully interpret FeNO values in this age group. Several factors related to the measurement conditions have been found to influence FeNO, such as expiratory flow, ambient NO and nasal contamination. Furthermore, the exposure to pre- and postnatal risk factors for respiratory morbidity has been shown to influence FeNO values. Therefore, these factors should always be assessed and their association with FeNO values in the specific study population should be evaluated and, eventually, controlled for.
- 1 January 2009
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 35 (1) , 21
Open AccessExhaled nitric oxide measurements in the first 2 years of life: methodological issues, clinical and epidemiological applications
Fractional exhaled nitric oxide (FeNO) is a useful tool to diagnose and monitor eosinophilic bronchial inflammation in asthmatic children and adults. In children younger than 2 years of age FeNO has been successfully measured both with the tidal breathing and with the single breath techniques. However, there are a number of methodological issues that need to be addressed in order to increase the reproducibility of the FeNO measurements within and between infants. Indeed, a standardized method to measure FeNO in the first 2 years of life would be extremely useful in order to meaningfully interpret FeNO values in this age group. Several factors related to the measurement conditions have been found to influence FeNO, such as expiratory flow, ambient NO and nasal contamination. Furthermore, the exposure to pre- and postnatal risk factors for respiratory morbidity has been shown to influence FeNO values. Therefore, these factors should always be assessed and their association with FeNO values in the specific study population should be evaluated and, eventually, controlled for.
- 1 July 2008
- Published by BMJ in Archives of Disease in Childhood
- Vol. 93 (7) , 619
Necrotising fasciitis complicating varicella
- 1 July 2008
- Published by BMJ in Archives of Disease in Childhood
- Vol. 93 (7) , 619
Necrotising fasciitis complicating varicella
- Open Access
- 1 January 2008
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 34 (1) , 5
Respiratory and gastrointestinal symptoms in esophageal atresia
- 1 January 2008
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 34 (1) , 5
Open AccessRespiratory and gastrointestinal symptoms in esophageal atresia
- 1 January 2008
- Published by Portico in Drugs of Today
- Vol. 44 (11) , 845-55
Montelukast sodium for exercise-induced asthma
Exercise is the most common trigger of bronchospasm in children with asthma. Exercise-induced bronchoconstriction (EIB) occurs in up to 90% of individuals with asthma who are not under antiinflammatory treatment and in about 40% of those with allergic rhinitis. EIB may be an overwhelming problem in childhood and adolescence, when physical activity is a prominent component of daily life. The importance for those with asthma to maintain regular physical activity is recognized by asthma guidelines, which include the recommendation of full participation in sporting activities in their goals for the management of asthma. Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. Montelukast sodium (Singulair, Merck & Co.) is a selective and orally active leukotriene receptor antagonist with demonstrated activity for treating asthma and allergic rhinitis. The effect of this drug in the prevention of EIB has been evaluated in a variety of studies in adults as well as in children. Both single-dose and regular-treatment studies showed that montelukast provides effective protection against EIB. Furthermore, chronic treatment with montelukast does not induce tolerance to the bronchoprotective effect over time. This aspect is particularly relevant for children, who tend to be active at frequent and irregular intervals throughout the day, and who therefore may benefit from around-the-clock pharmacologic protection.
- 1 January 2008
- Published by Portico in Drugs of Today
- Vol. 44 (11) , 845-55
Montelukast sodium for exercise-induced asthma
Exercise is the most common trigger of bronchospasm in children with asthma. Exercise-induced bronchoconstriction (EIB) occurs in up to 90% of individuals with asthma who are not under antiinflammatory treatment and in about 40% of those with allergic rhinitis. EIB may be an overwhelming problem in childhood and adolescence, when physical activity is a prominent component of daily life. The importance for those with asthma to maintain regular physical activity is recognized by asthma guidelines, which include the recommendation of full participation in sporting activities in their goals for the management of asthma. Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. Montelukast sodium (Singulair, Merck & Co.) is a selective and orally active leukotriene receptor antagonist with demonstrated activity for treating asthma and allergic rhinitis. The effect of this drug in the prevention of EIB has been evaluated in a variety of studies in adults as well as in children. Both single-dose and regular-treatment studies showed that montelukast provides effective protection against EIB. Furthermore, chronic treatment with montelukast does not induce tolerance to the bronchoprotective effect over time. This aspect is particularly relevant for children, who tend to be active at frequent and irregular intervals throughout the day, and who therefore may benefit from around-the-clock pharmacologic protection.
- 1 June 2007
- Published by Springer Nature in Infection
- Vol. 35 (3) , 209-210
Bacteremia Caused by Rothia mucilaginosa in a Patient with Shwachman-Diamond Syndrome
- 1 June 2007
- Published by Springer Nature in Infection
- Vol. 35 (3) , 209-210
Bacteremia Caused by Rothia mucilaginosa in a Patient with Shwachman-Diamond Syndrome
- Open Access
- 26 April 2006
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 28 (2) , 291-295
Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
The effect over time of regular treatment with montelukast (MNT) in inhibiting exercise-induced bronchoconstriction (EIB) has never been evaluated in children. The aim of the present study was to examine the preventive effect of MNT against EIB in children at different time-points over a 4-week treatment period.Thirty-two asthmatic children (aged 6–12 yrs) were enrolled in a double-blinded, randomised, parallel group design to receive a 4-week treatment with MNT (5 mg chewable tablets administered once daily in the evening) or placebo. Exercise challenge was performed at baseline and after 3, 7 and 28 days of treatment, 20–24 h after dosing.MNT was significantly more protective than placebo against EIB at each time. The mean percentage drop of forced expiratory volume in one second (FEV1) was 24.6, 13.6, 12.0 and 11.6 for MNT, and 24.4, 22.4, 21.8 and 21.0 for placebo, at baseline and after 3, 7 and 28 days, respectively. For each drug, no significant difference in the percentage drop of FEV1was found between different days.Regular treatment with montelukast provided significant protection against exercise-induced bronchoconstriction in asthmatic children over a 4-week period with no tolerance to the bronchoprotective effect.
- 26 April 2006
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 28 (2) , 291-295
Open AccessLack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
The effect over time of regular treatment with montelukast (MNT) in inhibiting exercise-induced bronchoconstriction (EIB) has never been evaluated in children. The aim of the present study was to examine the preventive effect of MNT against EIB in children at different time-points over a 4-week treatment period.Thirty-two asthmatic children (aged 6–12 yrs) were enrolled in a double-blinded, randomised, parallel group design to receive a 4-week treatment with MNT (5 mg chewable tablets administered once daily in the evening) or placebo. Exercise challenge was performed at baseline and after 3, 7 and 28 days of treatment, 20–24 h after dosing.MNT was significantly more protective than placebo against EIB at each time. The mean percentage drop of forced expiratory volume in one second (FEV1) was 24.6, 13.6, 12.0 and 11.6 for MNT, and 24.4, 22.4, 21.8 and 21.0 for placebo, at baseline and after 3, 7 and 28 days, respectively. For each drug, no significant difference in the percentage drop of FEV1was found between different days.Regular treatment with montelukast provided significant protection against exercise-induced bronchoconstriction in asthmatic children over a 4-week period with no tolerance to the bronchoprotective effect.